Integrated Nanotherapeutics' proprietary technology is particularly relevant and promising for the development of effective immunomodulatory and anticancer drugs to treat autoimmune and malignant diseases.
Autoimmune disease is a diverse collection of diseases that includes Crohn’s disease, rheumatoid arthritis, psoriasis, ulcerative Colitis and diabetes. It is among the top 10 leading causes of death in girls and women of up to 64 years of age in Canada and the U.S. At least 500 people are diagnosed with diabetes per day in Canada and 4,500 in the U.S. Diabetes is among the leading causes of kidney failure, heart disease and stroke, blindness, and nerve damage in limbs that often requires amputation. The life expectancy for patients with Type 1 and 2 diabetes may be shortened by as much as 15 and 2-10 years, respectively. There is a pressing need for new anti-inflammatory drugs and therapies for these diseases.
More than 190,000 Canadians and 1,600,000 Americans are diagnosed with cancer each year. On average, over 1,800 people die from cancer every day in North America. Research in cancer biology and anti-cancer drugs around the world continues to shed light on how cancer develops and ways to combat this devastating disease. Although chances of survival are improving due to advances in detection and treatment, patients still suffer from many unwanted side effects resulting from the toxic anti-cancer drugs. New forms of anti-cancer drugs that are effective in killing malignant cells but are safe for normal tissues are urgently needed.